Background and objective: Psoriasis is a chronic inflammatory skin
condition characterized by thick silvery plaques, commonly involving the elbow,
knees, lower back, and scalp. Psoriasis also affects the reproductive systems of
patients. Males with untreated psoriasis are at risk of impaired fertility due to
chronic systemic inflammation, which might affect the hormonal profile and sexual
accessory glands. In females, having psoriasis does not affect the chances of
getting pregnant. This study aims to assess the effect of psoriasis, as a chronic
inflammatory condition, on sex hormone profiles and seminal fluid parameters.
Methods: 87 male patients aged 18−50 with psoriasis who fulfilled the
inclusion criteria were included in the study and matched with healthy controls.
Demographic and clinical data, including age, severity, duration, and body mass
index (BMI) were recorded. All patients underwent a complete physical exam,
including a skin and andrological exam, in addition to ultrasound scrotum and
seminal fluid analysis. Blood sample tests were conducted for a complete hormonal
profile, including luteinizing hormone (LH), follicular stimulating hormone
(FSH), testosterone, and estradiol.
Results: The mean age of the case group was 39.5
Psoriasis is a chronic relapsing and recurrent autoimmune disease that affects the skin and joints [1, 2]. It is a worldwide disease affecting approximately 2% of the population [3], and more than 50% of psoriatic patients experience the disease after age 40 [4].
Psoriasis dramatically impairs quality of life and wellbeing, and in addition to skin manifestations, it carries a variety of emotional and psychological consequences [5].
The disease has an unpredictable course with variable features, including its distribution, course, and severity [2]. A psoriatic lesion is typically a well-demarcated circular silver-to-white plaque or red papule with a scaly surface [6], and joint involvement may coexist, resulting in psoriatic arthritis. It is evident now that psoriasis carries a multisystemic pathology that affects many areas other than the skin, including the eyes, cardiovascular system, renal system, reproductive system, and psychological states [7]. Additional epidemiologic reports have suggested that immune-mediated inflammation, such as in psoriasis, is associated with other comorbidities, including metabolic syndrome, cardiovascular disease, diabetes mellitus, and liver disease [8].
There is growing concern that methotrexate, used as a treatment for psoriasis
and other systemic diseases, is involved in developing infertility [9]. Recent
reports have emphasized that being in a state of chronic inflammation, such as
psoriasis, may lead to the development of male infertility, and the effect of
tumor necrosis factor (TNF) indicates the pathology behind this, a cytokine that
plays an essential role in both the pathogenesis of psoriasis and the regulation
of the spermatogenesis process, as it is secreted by germ cells [9, 10, 11]. It has
been found that the level of TNF-
This is a matched case-control study conducted in Jerash governmental hospital, affiliated with the Faculty of Medicine, Yarmouk University, from April 2018 to July 2020. An ethical approval number 12/1/2285 was provided by the institutional review board at King Abdullah University Hospital.
The study included male patients with psoriasis, aged between 18 and 50 years, who attended the dermatology clinic.
The included subjects had to have not been receiving topical treatment for at least eight weeks or active systemic treatment, including phototherapy, in the three months before enrollment; this applies to cases and controls. The study excluded patients with chronic medical conditions (e.g., diabetes mellitus and hypertension), smokers, alcoholics, and those with a history of infertility, as well as patients with testicular diseases (e.g., cryptorchidism, orchitis, scrotal trauma, genital tumors, and gross varicocele).
Of the 430 male psoriasis patients who attended the dermatology clinic during the study period, only 87 patients who fulfilled the inclusion criteria and agreed to participate in the study were assigned to the case group. Another 87 healthy individuals who were admitted for follow-up for various dermatological reasons were matched with the cases, according to age and sex, and considered controls. Information about age, BMI, psoriasis severity (using PASI score), and disease duration were recorded. The psoriasis area and severity index (PASI) is a quantitative rating score for measuring the severity of psoriatic lesions, based on area coverage and plaque appearance, including erythema, thickness, and scaling on the head, trunk, and upper and lower limbs, respectively. The maximum score was 72, and the minimum was 0. Additionally, all patients were subjected to physical examinations, including dermatologic and andrological examinations. A complete hormonal profile, including luteinizing hormone (LH), follicular stimulating hormone (FSH), testosterone, and estradiol, was also performed using seminal fluid analysis and blood tests. Psoriasis was clinically diagnosed, and severity was assessed using the PASI score. Scrotal ultrasounds were also performed to assess testicular volume and homogeneity and exclude any testicular disease.
Data were entered and analyzed using the Statistical Package for the Social
Sciences (SPSS) version 21 (SPSS Inc., Chicago, IL, USA). Descriptive statistics
were applied, and continuous data were presented as means and standard
deviations. Differences between cases and controls were assessed using
independent sample t-tests. Correlations between psoriasis parameters
(PASI score and disease duration), sperm, hormonal parameters, and BMI were
determined using Pearson correlation and expressed as P-values and
correlation coefficients (r). A P-value of
The study included 176 male patients (88 cases and 88 controls). The mean age of
the case group was 30.5
Study group | P (t) | |||
Case | Control | |||
Demographic and clinical information | ||||
Age | 39.5 |
39.2 |
0.793* (0.26) | |
Duration of psoriasis | 6.5 |
0 | 0 | |
BMI | 24.0 |
22.6 |
0.001* (3.26) | |
PASI score | 17.4 |
0 | 0 | |
Hormonal profile | ||||
Testosterone level ng/mL (NV 2.5–8.4) | 3.8 |
5.6 |
||
LH level mIU/L (NV 2.5–10) | 3.8 |
4.1 |
0.009* (−2.7) | |
FSH level mIU/L (NV 2.5–11) | 5.1 |
4.0 |
||
Estradiol level pg/mL (NV 10–35) | 39.7 |
25.8 |
||
Sperm parameters | ||||
Sperm concentration n |
21.7 |
65.9 |
||
Normal motility percent (NV |
28.3 |
61.6 |
||
Normal morphology percent (NV |
14.3 |
34.3 |
||
PASI, Psoriasis area and severity index; NV, normal value; E2, estradiol;
FSH, follicle-stimulating hormone; LH, luteinizing hormone; *P value; n
|
The mean testosterone levels were 3.8
Regression analysis demonstrated that age and PASI scores were significant
predictors of sperm concentration (P
Among patients with psoriasis, age was significantly negatively correlated with testosterone (−0.352, P = 0.01), sperm motility (−0.240, P = 0.01), and morphology (−0.202, P = 0.01). BMI was positively correlated with FSH (0.193, P = 0.01), and estradiol (0.203, P = 0.01) levels, and negatively correlated with sperm concentration (−0.249, P = 0.01), motility (−0.198, P = 0.05), and morphology (−0.205, P = 0.05). In addition, testosterone level showed a negative correlation with both FSH (−0.279, P = 0.01) and estradiol (−0.658, P = 0.01) levels, while there was a negative correlation between PASI score and sperm concentration (−0.519, P = 0.01).
Model (R |
B | SE | Beta | t | Sig. | 95% CI for B | ||
Lower bound | Upper bound | |||||||
Sperm conc. (0.565) | Age | −0.460 | 0.074 | −0.539 | −6.187 | 0.000 | −0.609 | −0.311 |
Duration of psoriasis | −0.041 | 0.120 | −0.030 | −0.341 | 0.734 | −0.282 | 0.200 | |
BMI | 0.155 | 0.193 | 0.070 | 0.803 | 0.425 | −0.231 | 0.541 | |
PASI score | −0.275 | 0.053 | −0.453 | −5.228 | 0.000 | −0.381 | −0.170 | |
Sperm motility (0.192) | Age | −0.603 | 0.205 | −0.349 | −2.945 | 0.005 | −1.012 | −0.193 |
Duration of psoriasis | −0.205 | 0.331 | −0.074 | −0.620 | 0.538 | −0.868 | 0.458 | |
BMI | 0.904 | 0.531 | 0.202 | 1.704 | 0.094 | −0.158 | 1.966 | |
PASI score | −0.137 | 0.145 | −0.111 | −0.944 | 0.349 | −0.427 | 0.153 | |
Sperm morphology (0.07) | Age | −0.111 | 0.101 | −0.140 | −1.097 | 0.277 | −0.312 | 0.091 |
Duration of psoriasis | 0.112 | 0.163 | 0.088 | 0.686 | 0.496 | −0.215 | 0.439 | |
BMI | 0.313 | 0.262 | 0.152 | 1.196 | 0.236 | −0.210 | 0.836 | |
PASI score | 0.062 | 0.071 | 0.110 | 0.873 | 0.386 | −0.081 | 0.205 |
This study explored semen analysis and sex hormonal profiles in male patients with psoriasis and their relationship to BMI and disease severity. It revealed an increased level of estradiol and decreased level of testosterone in the psoriasis group compared to the control group, which is similar to evidence reported by Caldarola et al. [18] and Cemil et al. [19], who pointed out an inverse correlation between PASI score and level of estradiol.
It is postulated that this hormonal imbalance of testosterone and estradiol may be accounted for by the evidence that the proinflammatory state and cytokines stimulate the aromatase enzyme, which converts androgens to estrogens [20, 21]. This hormonal imbalance was also reported by Tsilidis et al. [22] and was associated with high C-reactive protein levels, a systemic marker of inflammation, which supports the proinflammatory theory. The relationship between sex hormones and the etiology of psoriasis studied by Ozir et al. [23] found that estrogen and testosterone imbalance was an independent risk factor regarding psoriasis etiology in males. Some studies further mentioned a possible responsibility of sex hormones in reducing psoriasis severity, as supported by a marked reduction of C-reactive protein levels and improvement of psoriatic skin manifestations in 15 patients with psoriasis, and hypogonadism after treatment with a long-acting testosterone replacement therapy [24].
This sex hormonal disparity in proinflammatory conditions is not limited to testosterone. Tengstrand et al. [25] reported abnormalities in all sex hormones measured, including DHEAS, estrone, and estradiol in patients with rheumatoid arthritis. Furthermore, estrogen has been reported to have both pro-and anti-inflammatory roles [26].
The proinflammatory state, along with its sex hormonal disparity, has been indicated by the low level of seminal parameters in psoriasis patients, resulting in inflammation of the male genital accessory glands, as indicated by high seminal suPAR levels [18].
Semen analysis parameters of the case group were also noted to be lower than those of the control group, as shown in Table 1. Caldarola et al. [18] reported similar findings. Impaired testicular function in the form of a reduction in sperm morphology and motility in psoriasis settings was described in a study about testicular function and spondyloarthritis, where five participants had psoriatic arthritis [27].
Ataseven et al. [28] reported a significant decrease in proinflammatory indicators in patients with psoriasis treated with anti-TNF inhibitors compared to patients treated with interleukin antagonists. However, it is not yet evident whether the decrease in sperm production in patients with untreated psoriasis is primarily due to the effect of the disease itself on sperm production, or if it arises from the effect of the accompanying inflammatory status with high levels of proinflammatory cytokines that are tumor necrosis factor alpha, interleukin1 alpha and beta. Oxidative stress has been shown to decrease spermatogenesis, sperm motility, and membrane integrity of testicular somatic cells [10, 29]. Therefore, genital tract inflammation has been described as a significant comorbidity in psoriasis patients [30].
Data analysis showed a predictive effect of PASI scores on sperm concentration, which may reflect the effect of the disease on sexual functions. This was evident in another report that linked psoriasis with the development of sexual dysfunction, abnormal sperm parameters, and hypogonadism [31].
The study demonstrated a correlation between BMI and semen and hormonal parameters, and BMI was positively correlated with FSH and estradiol levels. Moreover, it was negatively correlated with sperm concentration, motility, and morphology, in contrast to what was reported by Caldarola et al. [18], who reported no association, but supported previous evidence of an inverse relationship between BMI and sperm motility [32].
It is evident that the longer the duration of untreated psoriasis, the higher
the chances of developing infertility [33]. However, it is not clear whether the
treatment of psoriasis can improve or worsen sexual dysfunction, as the treatment
for psoriasis is linked to the development of sexual dysfunction in both males
and females [34]. The average time within which a patient seeks psoriasis
treatment is around five to six months [35], and beyond that, permanent and
irreversible infertility may develop [36]. However, although the disease duration
reported by Caldarola et al. [18] (M = 15.8
The evaluation of seminal fluid analysis and hormone profiles among psoriasis patients showed marked variability. However, it was evident that the levels of sex hormones and seminal parameters were lower in patients with psoriasis than in the healthy controls. This may uncover the possibility of developing sexual dysfunction and infertility among patients with untreated psoriasis. Estradiol levels were found to be abnormally high in the case group, which may account for a possible compensatory mechanism of ongoing sexual dysfunction among psoriasis patients.
MA, KS, BJ, AA, YR, and SD contributed to study concept and design. MA, KS, and YR performed the data collection. MA, SD, BJ, and AA performed data analysis and interpretation. MA, KS, SD, and YR drafted the manuscript. MA, KS, BJ, AA, YR, and SD completed the critical revision of the manuscript. All authors read and approved the final version of the manuscript and contributed to the editorial changes of the manuscript.
Informed written consent was obtained from all participants after explaining the objectives and benefits of the research. Participants had the right to refuse participation or withdraw from the study at any point without any detriment to their health care. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of 13-1_2720. Meanwhile, an ethical approval number 12/1/2285 was provided by the institutional review board at King Abdullah University Hospital.
We would like to express our gratitude to all those who helped during the manuscript writing process.
This research received no external funding.
The authors declare no conflict of interest.